The pediatric periodic fever syndromes clinic nurse’s communication challenge
The pediatric periodic fever syndromes clinic nurse works in a specialty defined by a clinical paradox: the primary measure of treatment success is the absence of the event that brought the family to the clinic in the first place. When a child’s recurrent fever attacks stop or become less frequent after starting prophylactic medication, the family’s natural and rational inference is that the disease has resolved. The nurse must explain, across a spectrum of autoinflammatory conditions with different genetic foundations and different long-term risks, that the absence of attacks is not evidence the treatment can be stopped — it is evidence the treatment is working, and must continue for reasons that extend well beyond the symptom the family can observe.
Three recurrent misalignments define the communication challenge in the pediatric periodic fever clinic with particular urgency for nurses working with Spanish-speaking families.
The first is the PFAPA colchicine discontinuation after apparent improvement. A 6-year-old with PFAPA syndrome has been having monthly fever episodes since being started on colchicine three months earlier. Before colchicine, episodes came every three to four weeks. His mother observes that fevers now come only once a month and concludes that they are fading on their own — the medication is no longer needed. The nurse must explain the critical distinction between abortive and prophylactic therapy: prednisone aborts individual PFAPA episodes acutely through IL-1β and IL-18 suppression; colchicine does not abort episodes already in progress, but reduces the frequency with which they occur by inhibiting neutrophil microtubule assembly and the inflammasome priming that initiates the periodic cycle. Monthly fevers instead of every-three-week fevers is not spontaneous improvement — it is the colchicine working. Stopping the colchicine removes the prophylaxis and returns episodes to the pre-treatment frequency within weeks.
The second is the FMF colchicine discontinuation after a fever-free period. A 9-year-old with confirmed homozygous MEFV M694V/M694V familial Mediterranean fever mutation has been fever-free for six months on continuous colchicine. Her grandmother, who has been managing the medication at home, stopped giving it two months ago because she believed the disease had resolved. The nurse must explain two distinct facts: that MEFV mutations are permanent — they do not resolve because they are part of the patient’s genetic code, not an infection that clears — and that the long-term stakes of stopping colchicine in M694V homozygous FMF extend beyond fever attacks to AA amyloidosis, a life-threatening complication of chronic serum amyloid A protein accumulation that colchicine specifically prevents. Stopping colchicine removes both the attack prevention and the amyloidosis prevention simultaneously.
The third is the TRAPS etanercept discontinuation after sustained remission. A 13-year-old with TNF receptor-associated periodic syndrome confirmed by TNFRSF1A R92Q mutation has been attack-free for ten months on weekly etanercept injections. His father wants to stop the medication because it costs $2,400 per month even with insurance prior authorization and his son feels completely well. The nurse must explain that TNFRSF1A mutations impair the natural process of TNFR1 shedding from cell surfaces — a process that normally creates soluble TNF receptor decoys that neutralize free TNF before it can trigger the periodic inflammatory cascade — and that etanercept is pharmacologically supplying the soluble-receptor TNF-buffering function that Diego’s defective gene cannot. Ten attack-free months is not spontaneous remission of a genetic mutation; it is etanercept providing the TNF neutralization that Diego’s own receptor fails to provide. Stopping it removes that protection and returns attacks within months.
Three conversations from the pediatric periodic fever syndromes clinic:
Scenario 1: Mateo García-Hernández — 6 years old, Houston, Texas
Mateo García-Hernández had been having fevers since he was three years old. They came on a schedule that his mother Lucía García-Mendoza, a school crossing guard, had learned to predict to within a few days: every three to four weeks, Mateo would wake with a fever of 39 to 40 degrees Celsius, develop painful anterior cervical lymph nodes that made it hard for him to turn his head, and within 24 hours have a red throat and small white ulcers on the inside of his cheeks and lower lip. He was miserable for four to six days. By day seven he was always fully recovered, playing as if nothing had happened.
His pediatrician had initially treated each episode as strep throat. Six negative rapid strep tests and four negative throat cultures later, she had referred Mateo to the pediatric rheumatology and autoinflammatory disease clinic at the children’s hospital. The evaluation had been thorough: complete blood count during an episode showing white cell count 14,800 with neutrophilia and CRP 48 mg/L; normal ESR, ANA, and complement between episodes; genetic panel for hereditary periodic fevers negative for MEFV, MVK, TNFRSF1A, and NLRP3 mutations. The diagnosis had been PFAPA — periodic fever, aphthous stomatitis, pharyngitis, adenitis — a clinical diagnosis requiring regular fever episodes of specific duration and symptom pattern without other explanation.
The treatment plan had included: single-dose prednisone 1 mg/kg (maximum 30 mg) given at the onset of each fever to abort the episode; colchicine 0.5 mg once daily as prophylaxis to reduce episode frequency; and a discussion of tonsillectomy as a potential curative option to consider after six months of medical management. Lucía had been diligent with both medications. Over the three months since starting colchicine, Mateo had had three episodes — one every four weeks — each aborted within 24 hours by prednisone.
At the three-month follow-up, Lucía arrived with Mateo and his younger sister. She waited until the nurse had finished reviewing the episode log and then said, with the tentative confidence of a parent who had done research: “Mire, ya que Mateo está teniendo las fiebres nada más una vez al mes, yo creo que se está mejorando solo. Quiero preguntarle si podemos parar la colchicina porque ya casi no la necesita.” (Look, since Mateo is only having fevers once a month now, I think he is getting better on his own. I want to ask if we can stop the colchicine because he almost does not need it anymore.)
Pediatric periodic fever syndromes clinic nurse Carmen Soto-Espinoza sat across from her and placed the episode log between them. “Quiero explicarle algo importante sobre la colchicina — porque lo que le voy a decir no es lo que la mayoría de las familias esperan escuchar, y tiene mucho sentido que piense lo que está pensando.” (I want to explain something important about the colchicine — because what I am going to tell you is not what most families expect to hear, and it makes complete sense that you are thinking what you are thinking.)
Lucía nodded, watching her.
“La colchicina y la prednisolona hacen cosas completamente distintas. La prednisolona que le damos a Mateo al inicio de cada fiebre — esa sí para la fiebre. En cuatro a doce horas, la fiebre baja, los ganglios bajan, las llagas en la boca empiezan a sanar. Eso es lo que la prednisolona hace: para el episodio que ya empezó. Pero la prednisolona no evita el siguiente. De hecho, hay datos que sugieren que las familias que solo usan prednisolona sin colchicina a veces ven que los episodios vienen más seguido, porque la supresión brusca del ciclo inflamatorio puede interferir con la señal que lo reinicia más tarde.” (Prednisone and colchicine do completely different things. The prednisone we give Mateo at the start of each fever — that one does stop the fever. In four to twelve hours, the fever comes down, the lymph nodes reduce, the mouth sores start to heal. That is what prednisone does: stops the episode that has already started. But prednisone does not prevent the next one. In fact, there is data suggesting that families who use only prednisone without colchicine sometimes see episodes come more frequently, because the sudden suppression of the inflammatory cycle can interfere with the signal that resets it later.)
Mateo had climbed onto the exam table and was arranging the paper liner into origami while his mother listened.
“La colchicina hace algo diferente. No para la fiebre cuando ya empieza — si le damos colchicina el día que Mateo tiene fiebre, no va a bajarle la fiebre. Lo que hace la colchicina es trabajar todos los días entre los episodios para reducir la frecuencia con la que ocurren. El PFAPA produce un ciclo inflamatorio que se activa en el sistema inmune de Mateo cada tres o cuatro semanas. La colchicina inhibe el movimiento de los neutrófilos — esas son las células inmunes que lideran el ataque — y también inhibe parte del mecanismo que dispara el ciclo. El resultado es que el ciclo ocurre menos seguido.” (Colchicine does something different. It does not stop the fever when it has already started — if we give Mateo colchicine the day he has a fever, it will not bring the fever down. What colchicine does is work every day between episodes to reduce how often they occur. PFAPA produces an inflammatory cycle that activates in Mateo’s immune system every three to four weeks. Colchicine inhibits the movement of neutrophils — those are the immune cells that lead the attack — and also inhibits part of the mechanism that triggers the cycle. The result is that the cycle occurs less often.)
Lucía frowned slightly. “¿Entonces el mes entre las fiebres…?” (So the month between fevers…?)
“Es la colchicina funcionando. Antes de la colchicina, Mateo tenía fiebres cada tres o cuatro semanas. Ahora las tiene cada cuatro semanas, aproximadamente. Ese mes no es que las fiebres se estén yendo solas — es que la colchicina está reduciendo la frecuencia del ciclo. Si paramos la colchicina, el ciclo vuelve a su ritmo sin tratamiento: tres semanas, tres semanas, tres semanas. No a ninguna fiebre — a más fiebres.” (It is the colchicine working. Before colchicine, Mateo had fevers every three to four weeks. Now he has them approximately every four weeks. That month is not the fevers going away on their own — it is the colchicine reducing the frequency of the cycle. If we stop the colchicine, the cycle returns to its untreated rhythm: three weeks, three weeks, three weeks. Not to no fever — to more fevers.)
Lucía was quiet for a moment. “¿Para siempre?” (Forever?)
“No — y eso es diferente del FMF o del TRAPS, que tenemos que tratar para toda la vida. El PFAPA en niños tiene una buena probabilidad de desaparecer solo cuando Mateo llegue a la adolescencia — la mayoría de los niños con PFAPA se mejoran entre los ocho y los doce años, nadie sabe exactamente por qué, pero es un patrón que se ve consistentemente. Mientras tanto, tenemos tres opciones: continuar con colchicina más prednisolona, que es lo que estamos haciendo; o podemos hablar con el equipo de otorrinolaringología sobre la amigdalectomía. En niños con PFAPA, quitar las amígdalas es curativo en el cincuenta a ochenta por ciento de los casos, porque el tejido amigdalar parece ser el lugar donde se inicia el ciclo inflamatorio. Hay que evaluar si eso tiene sentido para Mateo. Por ahora, mientras evaluamos, la colchicina sigue siendo la mejor opción para reducir cuántas fiebres tiene.” (No — and that is different from FMF or TRAPS, which we have to treat for life. PFAPA in children has a good probability of disappearing on its own when Mateo reaches adolescence — most children with PFAPA get better between ages eight and twelve; nobody knows exactly why, but it is a pattern seen consistently. In the meantime, we have three options: continue with colchicine plus prednisone, which is what we are doing; or we can talk to the ear-nose-throat team about tonsillectomy. In children with PFAPA, removing the tonsils is curative in fifty to eighty percent of cases, because the tonsillar tissue appears to be where the inflammatory cycle starts. We need to evaluate whether that makes sense for Mateo. For now, while we evaluate, colchicine remains the best option to reduce how many fevers he has.)
Mateo looked up from his paper. “¿Me van a quitar las amígdalas?” (Are they going to take out my tonsils?)
“Todavía no decidimos eso — es una conversación para la próxima visita con toda la familia,” Carmen said. “Por ahora seguimos con la colchicina.” (We have not decided that yet — it is a conversation for the next visit with the whole family. For now we continue with the colchicine.)
Lucía exhaled. “Pensé que era buena noticia que fuera menos seguido.” (I thought it was good news that it was less frequent.)
“Es buena noticia — es la colchicina funcionando. La confusión es que esa buena noticia parece evidencia de que ya no se necesita, pero es exactamente lo contrario: es evidencia de que sí se necesita.” (It is good news — it is the colchicine working. The confusion is that that good news looks like evidence that it is no longer needed, but it is exactly the opposite: it is evidence that it is needed.)
Scenario 2: Valentina Espinoza-Cisneros — 9 years old, San Antonio, Texas
Valentina Espinoza-Cisneros had been diagnosed with familial Mediterranean fever at age seven after a workup that had spanned fourteen months and three emergency department visits for acute abdominal pain. At the time of diagnosis, the clinical picture was unmistakable in retrospect: fever to 39.5°C, severe peritoneal-sign abdominal pain lasting 24 to 48 hours (three ED visits had reached laparoscopy discussions before the fevers resolved), and a family history that included her maternal grandmother’s sister in Guadalajara who had died of kidney failure at 52 — the cause unknown but now, in light of Valentina’s diagnosis, almost certainly AA amyloidosis from untreated FMF.
The genetic panel had confirmed homozygous MEFV M694V/M694V — the highest-risk FMF genotype for both attack frequency and AA amyloidosis. Colchicine 0.5 mg twice daily had been started at age seven. In the two years since, Valentina had had two breakthrough attacks despite colchicine — one during a gastrointestinal illness that briefly compromised absorption, one in the first month of treatment before therapeutic levels were stable — and then nothing. Zero attacks in eighteen months of consistent treatment.
At the nine-year annual visit, Valentina arrived with Abuela Consuelo Espinoza-Vega, her maternal grandmother, who had taken over Valentina’s daily medication management when Valentina’s mother began working night shifts six months earlier. Valentina’s mother Rosa had called ahead to let the clinic know that Abuela Consuelo had stopped the colchicine approximately two months ago.
Abuela Consuelo arrived composed and direct. She sat across from pediatric autoinflammatory clinic nurse Ricardo Morales-Fuentes with Valentina beside her and placed her hands on her knees. “Yo paré la colchicina porque Valentina lleva seis meses sin fiebres y a mí no me parece lógico darle pastillas para una enfermedad que ya no tiene. Con todo respeto — yo cuidé a Valentina de bebé y sé cuando está bien. Está bien.” (I stopped the colchicine because Valentina has gone six months without fevers and it does not seem logical to me to give her pills for a disease she no longer has. With all due respect — I cared for Valentina as a baby and I know when she is well. She is well.)
Valentina watched her grandmother, then looked at the nurse.
Ricardo brought up Valentina’s chart and turned the screen slightly so Abuela Consuelo could see the genetic result. “Abuela Consuelo, quiero explicarle algo sobre la mutación que tiene Valentina, porque la conclusión que usted sacó — que seis meses sin fiebre significa que la enfermedad se fue — tiene mucho sentido si estamos hablando de una infección. Pero el FMF de Valentina no es una infección — es una mutación en un gen que ella nació con. Y los genes no desaparecen.” (Abuela Consuelo, I want to explain something about the mutation that Valentina has, because the conclusion you drew — that six months without fever means the disease went away — makes complete sense if we are talking about an infection. But Valentina’s FMF is not an infection — it is a mutation in a gene she was born with. And genes do not disappear.)
Abuela Consuelo met his gaze. “Explíqueme.” (Explain it to me.)
“El gen que tiene Valentina — el MEFV — produce una proteína que normalmente controla una parte del sistema inflamatorio. La mutación M694V que tiene Valentina hace que esa proteína no funcione bien — el sistema inflamatorio queda sin freno en ciertas situaciones, y el resultado son los episodios de fiebre y dolor abdominal que ustedes conocen. Esa mutación existe en cada célula del cuerpo de Valentina, en los dos cromosomas — los dos copies del gen están afectados. No se va con el tiempo. No se cura con la edad. Está ahí para toda la vida de Valentina.” (The gene Valentina has — MEFV — produces a protein that normally controls a part of the inflammatory system. The M694V mutation Valentina has makes that protein not work well — the inflammatory system loses its brake in certain situations, and the result is the fever and abdominal pain episodes you know. That mutation exists in every cell of Valentina’s body, in both chromosomes — both copies of the gene are affected. It does not go away with time. It is not cured with age. It is there for Valentina’s whole life.)
Abuela Consuelo looked at her granddaughter. Valentina was watching the screen. “¿Y los seis meses sin fiebre?” (And the six months without fever?)
“Son exactamente la colchicina funcionando. La colchicina no cura la mutación — eso no es posible. Lo que hace es bloquear el camino que la mutación tiene abierto. Mientras Valentina toma la colchicina, ese camino está bloqueado y el sistema inflamatorio no se dispara. Cuando Valentina deja la colchicina, el bloqueo desaparece, la mutación sigue ahí, y el camino inflamatorio está abierto de nuevo. Para la mayoria de los pacientes con FMF que paran la colchicina, los ataques vuelven en dos o tres meses. Valentina lleva dos meses sin colchicina — estamos en el momento en que probablemente volveraán si no la reiniciamos.” (It is exactly the colchicine working. Colchicine does not cure the mutation — that is not possible. What it does is block the pathway the mutation has opened. While Valentina takes colchicine, that pathway is blocked and the inflammatory system does not fire. When Valentina stops colchicine, the block disappears, the mutation is still there, and the inflammatory pathway is open again. For most FMF patients who stop colchicine, attacks return within two to three months. Valentina has been without colchicine for two months — we are at the point where they will probably return if we do not restart it.)
Abuela Consuelo straightened slightly. “¿Y si vuelven los ataques, no simplemente le damos otra vez?” (And if the attacks return, can we not simply give it again?)
“Sí — pero necesito explicarle por qué no queremos esperar a que vuelvan los ataques. Hay una consecuencia del FMF que no es las fiebres — y es más seria que las fiebres. Se llama amiloidosis AA. Cuando el FMF no está bien controlado, el hígado produce una proteína inflamatoria llamada amiloide A en respuesta a la inflamación crónica del sistema — no solo durante los ataques, sino también entre los ataques, porque la mutación de Valentina produce inflamación de bajo grado continua incluso cuando no hay fiebre. Esa proteína amiloide A se acumula durante años en los riñones, el hígado, y el bazo. Con el tiempo — típicamente después de diez a veinte años de FMF mal controlado — los riñones empiezan a fallar. Se llama nefropatía amiloide.” (Yes — but I need to explain to you why we do not want to wait for the attacks to return. There is a consequence of FMF that is not the fevers — and it is more serious than the fevers. It is called AA amyloidosis. When FMF is not well controlled, the liver produces an inflammatory protein called amyloid A in response to the chronic inflammation of the system — not only during attacks, but also between attacks, because Valentina’s mutation produces continuous low-grade inflammation even when there is no fever. That amyloid A protein accumulates over years in the kidneys, liver, and spleen. Over time — typically after ten to twenty years of poorly controlled FMF — the kidneys begin to fail. It is called amyloid nephropathy.)
Abuela Consuelo’s face changed. She looked at Valentina. “¿Los riñones?” (The kidneys?)
“Sí. Y la mutación de Valentina — la M694V homocigótica, que significa que los dos copies del gen están afectados — es la de mayor riesgo para la amiloidosis. Sin colchicina continua, el riesgo de amiloidosis durante la vida de Valentina es entre el cuarenta y el sesenta por ciento. Con colchicina continua, ese riesgo baja drásticamente porque la colchicina reduce tanto la inflamación durante los ataques como la inflamación de bajo grado entre los ataques. La colchicina en el FMF de Valentina no es un medicamento para cuando está mal — es un medicamento para proteger los riñones de Valentina para cuando tenga veinte, treinta, cuarenta años.” (Yes. And Valentina’s mutation — M694V homozygous, meaning both copies of the gene are affected — is the highest risk for amyloidosis. Without continuous colchicine, the lifetime risk of amyloidosis for Valentina is between forty and sixty percent. With continuous colchicine, that risk drops dramatically because colchicine reduces both the inflammation during attacks and the low-grade inflammation between attacks. Colchicine in Valentina’s FMF is not a medication for when she is sick — it is a medication to protect Valentina’s kidneys for when she is twenty, thirty, forty years old.)
There was silence. Valentina looked at her grandmother. “Abuela,” she said quietly. “¿La tía abuela Rosario murió de eso?” (Grandma — did great-aunt Rosario die of that?)
Abuela Consuelo did not answer immediately. She looked at the floor, then at the nurse. “¿Cuándo puede empezar de nuevo?” (When can she start again?)
“Hoy. La reiniciamos hoy con la misma dosis: 0.5 miligramos en la mañana y 0.5 en la noche. El cuerpo de Valentina va a responder rápido — en dos semanas estará de vuelta a los niveles terapéuticos. Lo que le pido es que si en algún momento siente que la dosis es correcta o que las pastillas ya no son necesarias, me llame antes de parar. Eso es lo único que le pido.” (Today. We restart today with the same dose: 0.5 milligrams in the morning and 0.5 at night. Valentina’s body will respond quickly — in two weeks she will be back to therapeutic levels. What I ask is that if at any point you feel the dose is correct or that the pills are no longer necessary, call me before stopping. That is the only thing I ask.)
Abuela Consuelo nodded once. “Entendido.” (Understood.)
Scenario 3: Diego Herrera-Ramírez — 13 years old, Dallas, Texas
Diego Herrera-Ramírez had been the medical mystery in his family for four years before the diagnosis. The attacks had started at age nine: fever to 39°C lasting eight to twelve days, accompanied by swelling around both eyes that his parents had initially thought was allergy, severe muscle pain that migrated from the thighs to the arms over the course of an attack, and a non-itchy reddish rash that appeared on his trunk and spread to his limbs. His father Roberto Herrera-Cisneros, a civil engineer, had organized everything: a binder with the date and duration of every attack since the first one, photographs of the periorbital swelling and the rash, the results of the seventeen blood tests and two bone marrow biopsies obtained during the diagnostic odyssey.
The diagnosis — TNF receptor-associated periodic syndrome, TNFRSF1A R92Q heterozygous mutation — had come after a referral to the academic medical center’s autoinflammatory disease program. The pediatric rheumatologist had explained: the R92Q mutation was a lower-penetrance variant that some registries classified as a variant of uncertain significance, but Diego’s clinical phenotype was unambiguous, his attack pattern matched TRAPS criteria, and no other diagnosis explained the combination of prolonged attacks, periorbital edema, migratory myalgia, and mononuclear cell-predominant inflammation on attack biopsy. Etanercept 25 milligrams subcutaneous weekly had been started fourteen months earlier.
In the first two months, Diego had had one partial attack — three days of fever and mild periorbital swelling, less severe than any previous full attack, then spontaneous resolution. In the twelve months since, nothing. Zero attacks. He had attended school every day except during a respiratory virus in February. He had rejoined the school soccer team. He had grown 5 centimeters.
His father Roberto arrived at the fourteen-month visit with the binder, as always, and a printed summary of the etanercept cost history. “Nurse, necesito hablar sobre el etanercept. Con el seguro y el copago, esto nos cuesta 2,400 dólares al mes. Diego lleva diez meses sin ningún ataque. Está completamente bien — lo puede ver usted mismo, está jugando fútbol, va a la escuela todos los días. Yo quiero saber si tiene sentido seguir con una medicina tan cara cuando el niño está perfectamente bien.” (Nurse, I need to talk about etanercept. With insurance and the copay, this costs us $2,400 a month. Diego has had no attacks for ten months. He is completely well — you can see for yourself, he is playing soccer, going to school every day. I want to know if it makes sense to continue with such an expensive medication when the boy is perfectly well.)
Diego sat beside his father, already watching the nurse with the particular attention of a teenager who had been through enough diagnostic appointments to understand that the nurse’s answer was going to matter.
Pediatric autoinflammatory disease clinic nurse María Cisneros-Hernández brought up Diego’s genetic result and the attack log simultaneously. “Señor Herrera, primero — lo que usted ve cuando mira a Diego, que está perfectamente bien, que juega fútbol, que no le duele nada — eso es real. Eso no es mi imaginación ni la suya. Diego está bien. Y quiero explicarle por qué está bien, porque la respuesta a esa pregunta es exactamente la razón por la que no podemos parar el etanercept.” (Mr. Herrera, first — what you see when you look at Diego, that he is perfectly well, playing soccer, nothing hurts — that is real. That is not my imagination or yours. Diego is well. And I want to explain to you why he is well, because the answer to that question is exactly the reason we cannot stop etanercept.)
Roberto placed the binder on the table but did not open it. “Escucho.” (I’m listening.)
“El gen de Diego — el TNFRSF1A — produce un receptor para una proteína inflamatoria que se llama TNF. En una persona sin la mutación de Diego, ese receptor hace dos cosas: primero, recibe la señal del TNF cuando la célula necesita activarse; pero segundo — y esto es lo importante — el receptor también se desprende de la superficie de la célula y flota en la sangre como una trampa. Ese receptor libre en la sangre atrapa el TNF antes de que llegue a otras células, controlando cuánta inflamación ocurre. Es el sistema de freno natural para el TNF.” (Diego’s gene — TNFRSF1A — produces a receptor for an inflammatory protein called TNF. In a person without Diego’s mutation, that receptor does two things: first, it receives the TNF signal when the cell needs to activate; but second — and this is the important part — the receptor also sheds from the surface of the cell and floats in the blood as a trap. That free receptor in the blood captures TNF before it reaches other cells, controlling how much inflammation occurs. It is the natural braking system for TNF.)
Roberto was still. Diego had leaned slightly forward.
“La mutación R92Q de Diego hace que ese receptor no se desprenda bien. Se queda en la célula en vez de flotar en la sangre. El resultado es que hay menos trampas para el TNF en la sangre de Diego, el TNF llega a las células sin ser atrapado, y el sistema inflamatorio se activa en exceso — produciendo los ataques de fiebre de dos semanas, la inflamación alrededor de los ojos, el dolor muscular que usted documentó en ese cuaderno. Esa mutación está en cada célula del cuerpo de Diego y va a estar ahí para siempre. No se fue. No se va a ir.” (Diego’s R92Q mutation makes that receptor not shed well. It stays on the cell instead of floating in the blood. The result is that there are fewer TNF traps in Diego’s blood, TNF reaches cells without being captured, and the inflammatory system overactivates — producing the two-week fever attacks, the swelling around the eyes, the muscle pain you documented in that binder. That mutation is in every cell of Diego’s body and will be there permanently. It did not go away. It is not going to go away.)
Roberto looked at his son for a moment. “¿Y el etanercept?” (And etanercept?)
“El etanercept es una copia artificial del receptor flotante que el gen de Diego no produce suficientemente. Cuando le inyectamos etanercept una vez a la semana, esa molécula circula en la sangre de Diego y atrapa el TNF exactamente como debería hacerlo el receptor de Diego si funcionara bien. Le está dando a Diego lo que su propio gen no puede darle. Cuando Diego lleva diez meses sin ataques, no es que la enfermedad se fue — es que el etanercept está atrapando el TNF cada semana, igual que el receptor sano atraparía si no hubiera mutación. Si quitamos el etanercept, la trampa desaparece. El gen mutado sigue ahí. En dos a cuatro meses, la mayoría de los pacientes con TRAPS tienen un ataque.” (Etanercept is an artificial copy of the floating receptor that Diego’s gene does not produce sufficiently. When we inject etanercept once a week, that molecule circulates in Diego’s blood and captures TNF exactly as Diego’s receptor should if it were working properly. It is giving Diego what his own gene cannot give him. When Diego has had no attacks for ten months, it is not that the disease went away — it is that etanercept is trapping TNF every week, just as a healthy receptor would trap it if there were no mutation. If we remove etanercept, the trap disappears. The mutated gene is still there. In two to four months, most TRAPS patients have an attack.)
Roberto was quiet. Diego spoke. “¿Si paro, vuelvo a cómo estaba antes?” (If I stop, do I go back to how I was before?)
“Probablemente. Y eso significa: dos semanas sin poder ir a la escuela, los ojos hinchados, el dolor en las piernas que no te deja dormir. Todo eso que está en el cuaderno de tu papá.” (Probably. And that means: two weeks unable to go to school, swollen eyes, the leg pain that does not let you sleep. All of that that is in your father’s binder.)
Diego looked at his father.
Roberto tapped the binder. “¿Y el costo? No puedo ignorar el costo.” (And the cost? I cannot ignore the cost.)
“Tampoco yo. Hay dos cosas que quiero hacer con usted hoy. Primera: hablar con la farmacia de especialidades y con el coordinador de beneficios del hospital sobre los programas de asistencia del fabricante del etanercept — existen para exactamente esta situación, y no siempre se activan automáticamente. Segunda: el equipo del médico va a revisar si Diego es candidato para el protocolo de dosificación extendida — hay datos para ciertos pacientes con TRAPS en remisión sostenida de pasar de inyecciones semanales a cada diez a catorce días. Eso reducía el costo directamente. Lo que no podemos hacer es parar completamente sin datos de que el TRAPS de Diego está en remisión genética, porque la genética no cambia.” (Neither can I. There are two things I want to do with you today. First: speak with the specialty pharmacy and the hospital benefits coordinator about the manufacturer assistance programs for etanercept — they exist for exactly this situation, and they are not always automatically activated. Second: the doctor’s team will review whether Diego is a candidate for extended dosing protocols — there is data for certain TRAPS patients in sustained remission to move from weekly injections to every ten to fourteen days. That would reduce the cost directly. What we cannot do is stop completely without data showing Diego’s TRAPS is in genetic remission, because the genetics do not change.)
Roberto looked at the attack log on Diego’s chart — the fourteen hospitalizations in four years before diagnosis, the seventeen blood tests, the two bone marrow biopsies. Then at his son, who was sitting comfortably, healthy, the periorbital edema completely absent. “Hablen con la farmacia,” he said. “Pero el medicamento sigue.” (Talk to the pharmacy. But the medication continues.)
Diego nodded. “Gracias,” he said to the nurse. “Por explicarle.” (Thank you. For explaining it to him.)